Latest news with #VitorPapao
Al Etihad
14-05-2025
- Health
- Al Etihad
ADPHC, Gilead Sciences Ireland partner to further enhance public health efforts in Abu Dhabi
14 May 2025 21:06 ABU DHABI (ALETIHAD)The Abu Dhabi Public Health Centre (ADPHC) has partnered with Gilead Sciences Ireland to enhance disease prevention, early detection, and public awareness in key health areas in Abu two-year initiative establishes a framework for collaboration between ADPHC and Gilead Sciences across two core pillars, including disease awareness and education campaigns, and screening and early detection and diagnosis. The partnership will focus on blood-borne viruses, including hepatitis B (HBV), hepatitis C (HCV), and Faisal Al Ahbabi, Acting Executive Director of Communicable Diseases Sector, Abu Dhabi Public Health Centre and Vitor Papao, General Manager, Gilead Sciences, signed the agreement during the 25th IUHPE World Conference on Health Rashid Al Suwaidi, Director General of Abu Dhabi Public Health Centre, said," "This partnership marks a strategic step in strengthening our response to public health challenges. By collaborating with Gilead Sciences, we aim to amplify our efforts in disease awareness, early screening, and empowering the public and healthcare providers. Together, we will work to build a healthier and more informed population in Abu Dhabi."Vitor Papao, General Manager of Gilead Sciences, said, "At Gilead Sciences, we believe in the power of partnership to transform public health. We are proud to join hands with ADPHC to deliver innovative, evidence-based solutions to some of the most pressing health concerns. This collaboration reflects our long-standing commitment to improving lives through education and early intervention."The agreement includes co-developing public awareness campaigns across digital and traditional platforms, promoting proactive screening among high-risk populations, and joint initiatives to align local practices with global standards of parties will explore digital solutions to enhance patient tracking and improve referral and follow-up aims to boost the population's overall health through integrated prevention, screening and intervention systems. In 2024, the centre released its Public Health System Strengthening Report (PHSSR), emphasising the need to target non-communicable diseases, and improve early detection through proactive campaigns and systemic enhancements. Gilead Sciences brings to the collaboration a wealth of global experience, operating in over 35 countries with a proven track record in disease prevention and therapeutic innovation. Through the initiative, Gilead Sciences will leverage its international expertise and local presence to support Abu Dhabi's goals of enhancing healthcare awareness, optimising screening protocols, and improving care linkages across the health system. Source: Aletihad - Abu Dhabi
Al Etihad
17-04-2025
- Health
- Al Etihad
DoH partners with Gilead Sciences to propel healthcare innovation, cell therapy advancement
17 Apr 2025 18:59 ABU DHABI (ALETIHAD)As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW).As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the the presence of Dr. Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said, 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences, commented, 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.'
Zawya
17-04-2025
- Health
- Zawya
DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement
This collaboration supports Abu Dhabi's commitment to building a resilient healthcare ecosystem that prioritises preventative, personalised and comprehensive care Abu Dhabi, UAE: As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW). As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the emirate In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences. Reflecting Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for communities. This strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare practices. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said: 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences commented: 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our l contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.' ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being. ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health. For more information, visit About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@ About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017. About Kite Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing.
